Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Commun. 2014;5:3083. doi: 10.1038/ncomms4083.

Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease.

Author information

1
1] Department of Chemical and Biological Engineering, Chalmers University of Technology, Kamivangen 10, Gothenburg SE-412 96, Sweden [2].
2
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala SE-751 85, Sweden.
3
1] Department of Proteomics, KTH-Royal Institute of Technology, Stockholm SE-106 91, Sweden [2] Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm SE-171 21, Sweden.
4
1] Department of Chemical and Biological Engineering, Chalmers University of Technology, Kamivangen 10, Gothenburg SE-412 96, Sweden [2] Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm SE-171 21, Sweden.

Abstract

Several liver disorders result from perturbations in the metabolism of hepatocytes, and their underlying mechanisms can be outlined through the use of genome-scale metabolic models (GEMs). Here we reconstruct a consensus GEM for hepatocytes, which we call iHepatocytes2322, that extends previous models by including an extensive description of lipid metabolism. We build iHepatocytes2322 using Human Metabolic Reaction 2.0 database and proteomics data in Human Protein Atlas, which experimentally validates the incorporated reactions. The reconstruction process enables improved annotation of the proteomics data using the network centric view of iHepatocytes2322. We then use iHepatocytes2322 to analyse transcriptomics data obtained from patients with non-alcoholic fatty liver disease. We show that blood concentrations of chondroitin and heparan sulphates are suitable for diagnosing non-alcoholic steatohepatitis and for the staging of non-alcoholic fatty liver disease. Furthermore, we observe serine deficiency in patients with NASH and identify PSPH, SHMT1 and BCAT1 as potential therapeutic targets for the treatment of non-alcoholic steatohepatitis.

Comment in

PMID:
24419221
DOI:
10.1038/ncomms4083
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center